Aclaris Therapeutics (ACRS) Other Non-Current Assets (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Other Non-Current Assets of $2.4 million for Q1 2026, down 24.85% year-over-year from $3.2 million in Q1 2025, and down 14.54% quarter-over-quarter from $2.8 million in Q4 2025.
Aclaris Therapeutics (ACRS) Other Non-Current Assets (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Other Non-Current Assets history runs 13 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 24.85% year-over-year to $2.4 million; the TTM figure through Mar 2026 stood at $2.4 million (down 24.85% YoY), while the FY2025 annual figure was $2.8 million, down 9.62% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $2.4 million, down from $2.8 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $4.2 million in Q4 2023, with the low at $2.4 million in Q1 2026.
- The 5-year median for Other Non-Current Assets is $3.1 million (2024), against an average of $3.1 million.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets soared 52.2% in 2023, then declined 26.26% in 2024.
- Aclaris Therapeutics' Other Non-Current Assets stood at $2.7 million in 2022, then surged by 52.2% to $4.2 million in 2023, then slipped by 26.26% to $3.1 million in 2024, then retreated by 9.62% to $2.8 million in 2025, then decreased by 14.54% to $2.4 million in 2026.
- Business Quant data shows ACRS's Other Non-Current Assets at $2.4 million in Q1 2026, $2.8 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.20 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 2.77 Mn |
| Sep 30, 2025 | 2.83 Mn |
| Jun 30, 2025 | 2.99 Mn |
| Mar 31, 2025 | 3.15 Mn |
| Dec 31, 2024 | 3.07 Mn |
| Sep 30, 2024 | 3.22 Mn |
| Jun 30, 2024 | 3.37 Mn |
| Mar 31, 2024 | 4.00 Mn |
| Dec 31, 2023 | 4.16 Mn |
| Sep 30, 2023 | 2.66 Mn |
| Jun 30, 2023 | 2.89 Mn |
| Mar 31, 2023 | 3.28 Mn |
| Dec 31, 2022 | 2.73 Mn |
| Sep 30, 2022 | 2.92 Mn |
| Jun 30, 2022 | 3.11 Mn |
| Mar 31, 2022 | 3.38 Mn |
| Dec 31, 2021 | 3.55 Mn |
| Sep 30, 2021 | 3.74 Mn |